The increasing resistance of pathogenic bacteria to known antibiotics is an urgent problem—there are increasingly frequent reports of multidrug-resistant pathogens against which even reserve antibiotics are ineffective. At the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), an HZI site in cooperation with Saarland University, scientists are using myxobacteria as a source of new active compounds.
These soil-dwelling bacteria have, so to speak, a long history at the HZI, as it was the two Braunschweig-based scientists Prof. Hans Reichenbach and Prof. Gerhard Höfle who, through their decades of work, laid the foundation for an extensive global collection of myxobacteria. This collection is still used today as a rich source of new active compounds with interesting chemical structures and often extremely potent biological activities. This microbial treasure trove has since grown to more than 14,000 myxobacterial strains, and in the HIPS department “Microbial Natural Products,” led by Prof. Rolf Müller, researchers are working intensively to unlock as many of the myxobacteria’s chemical secrets as possible. After all, every newly discovered substance brings with it the hope of having found a molecule that might be suitable for further development into a pharmaceutical active compound.